Related Experiment Videos
Social phobia: the need for treatment
1Imperial College of Medicine, St Mary's Hospital, London, UK.
International Clinical Psychopharmacology
|February 18, 1998
Summary
Social phobia causes significant dysfunction, comparable to depression, often leading to secondary health issues. Moclobemide demonstrates efficacy in treating social phobia, particularly in severe cases.
Area of Science:
- Psychiatry
- Clinical Psychology
- Pharmacology
Background:
- Social phobia significantly impairs social and occupational functioning.
- Disability from social phobia can be as severe as or more severe than chronic disorders like depression.
- Comorbidity frequently develops secondary to social phobia, exacerbating impairment.
Purpose of the Study:
- To review treatment modalities for social phobia.
- To detail the efficacy of moclobemide in social phobia treatment.
- To analyze treatment outcomes based on initial symptom severity.
Main Methods:
- Review of existing literature on social phobia treatments.
- Analysis of moclobemide's efficacy in short- and long-term treatment.
- Subanalysis comparing treatment response in severe versus moderate social phobia.
Main Results:
- Moclobemide shows efficacy in both short- and long-term treatment of social phobia.
- Treatment efficacy is more pronounced in patients with severe social phobia compared to those with moderate severity.
- Findings highlight the clinical relevance of considering initial severity in treatment selection.
Conclusions:
- Moclobemide is an effective treatment option for social phobia.
- Tailoring treatment intensity based on initial severity may optimize outcomes.
- Addressing social phobia effectively can reduce overall patient disability and comorbidity.